Nissan Motor Co. faced a 4.4% decline in global sales for 2025, with a sharper 6.7% drop in December, as weakness in key markets like China and Europe offset gains in North America.
Suzuki Motor Corporation has surpassed Nissan in worldwide vehicle sales for 2025, securing its position as Japan's third-largest automaker. The shift highlights Suzuki's growing strength in emerging markets and Nissan's ongoing struggles to regain momentum.
Toyota Motor posts record annual sales of 10.5 million vehicles, solidifying its global leadership. As its shares show strong long-term gains, investors are weighing future growth potential against tariff pressures and valuation concerns.
Marketing technology firm Zeta Global announces a strategic collaboration with OpenAI, aiming to deeply integrate advanced AI into its platform. The move, coupled with positive buzz from CES 2026, sharpens its competitive edge in a sector dominated by giants like Salesforce and Adobe.
Heineken launches a global marketing initiative celebrating shared passions in sports and music, aiming to foster real-world connections amid declining U.S. sales and a competitive import beer market.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Rosenblatt Securities raised its rating on cybersecurity firm Fortinet ahead of its Q4 earnings, citing a favorable hardware refresh cycle, effective sales strategies, and supportive tax incentives as key growth drivers.
Buoyed by robust demand for its premium iPhone 17 Pro models, Apple is projected to report its highest quarterly iPhone sales increase in over four years. Analysts spotlight a pivotal AI deal with Google's Gemini as a key future growth lever, even as the tech giant navigates supply chain cost pressures.
KTM's preliminary 2025 financial results reveal a steep decline in revenue and sales, casting doubt on the efficacy of recent restructuring efforts and raising questions about the brand's near-term recovery trajectory.
While small-cap stocks have broadly underperformed, recent insider buying activity points to potential value in select global companies. We examine three firms where leadership is putting their own capital to work.
A final arbitration ruling in favor of Venture Global LNG against Spain's Repsol resolves a high-stakes contractual dispute, providing clarity on cash flows and bolstering confidence in the company's long-term project viability amid volatile energy markets.
President Trump's apparent endorsement of a weaker dollar is not mere rhetoric but a strategic pillar of his economic agenda, aimed at boosting US competitiveness and narrowing the trade deficit, with significant implications for global central banks and currency markets.
The Kospi index plunged over 5% in its sharpest drop since April, halting program trading and dragging down chip giants Samsung and SK Hynix. The selloff, fueled by global risk-off sentiment and doubts over AI spending, tests the resilience of one of the world's hottest equity markets.
Interparfums (IPAR) has locked in exclusive long-term licenses for the Nautica and David Beckham fragrance portfolios, aiming to revitalize the brands and expand their digital footprint globally. The deals signal a strategic push into mainstream lifestyle and celebrity scents.
Shares of marketing software firm Zeta Global have tumbled over 10% in a week, sparking debate among investors. While a key valuation model suggests the stock is significantly undervalued, market sentiment remains cautious amid broader tech volatility.
Brookfield Renewable Partners (BEP) reported robust 2025 financial results, highlighted by record deployment and a strategic pivot to capitalize on surging global electricity demand driven by AI and reindustrialization.
Tesla is discontinuing its flagship Model S sedan and Model X SUV, a strategic shift underscored by plummeting sales figures and Elon Musk's pivot toward robotics and autonomy.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Lockheed Martin capped a year of robust sales growth with a historic $194 billion order backlog, driven by soaring demand for its advanced defense systems. The aerospace giant announced plans for a significant 'step function' increase in capital investment for 2026 to ramp up production of missiles and next-generation capabilities.
